Quantcast

Nuvo Research announces director election results of its annual general meeting

June 11, 2014

MISSISSAUGA, ON, June 11, 2014 /PRNewswire/ – Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that at its 2014 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 30, 2014 were elected as directors of the Company.

The detailed results of the votes by proxy are as follows:

    Director Nominees

                                     NUMBER OF SHARES       PERCENTAGE OF
                                                           VOTES CAST

    ===

    FOR                         WITHHELD     FOR          WITHHELD
    ===                         ========     ===          ========

    Daniel Chicoine              3,280,929        196,987      94.34      5.66
    ===============              =========        =======      =====      ====

    David A. Copeland            3,279,013        198,903      94.28      5.72
    =================            =========        =======      =====      ====

    Anthony E. Dobranowski       3,279,784        198,132      94.30      5.70
    ======================       =========        =======      =====      ====

    Dr. Henrich R.K. Guntermann  3,345,441        132,475      96.19      3.81
    ===========================  =========        =======      =====      ====

    Dr. Klaus von Lindeiner      3,280,884        197,032      94.33      5.67
    =======================      =========        =======      =====      ====

    John C. London               3,280,958        196,958      94.34      5.66
    ==============               =========        =======      =====      ====

    Dr. Jacques Messier          3,280,127        197,789      94.31      5.69
    ===================          =========        =======      =====      ====

    Dr. Theodore H. Stanley      3,285,630        192,286      94.47      5.53
    =======================      =========        =======      =====      ====

About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the creation of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders. For additional company information visit
www.nuvoresearch.com.

SOURCE Nuvo Research Inc.


Source: PR Newswire



comments powered by Disqus